Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Bergman

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Pediatric Research|September 1, 1996
Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerationsA J Bergman, M S Van der Knaap, J A Smeitink, et al.
Human Mutation|June 20, 1998
Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countriesA J Bergman, I E van den Berg, W Brink, et al.
Human Genetics|January 1, 1996
Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationshipJ K Ploos van Amstel, A J Bergman, E A van Beurden, et al.
Clinical Pharmacology and Therapeutics|June 27, 2008
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsR Krishna, A J Bergman, B Jin, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Pediatric Research|September 1, 1996
Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerationsA J Bergman, M S Van der Knaap, J A Smeitink, et al.
Human Mutation|June 20, 1998
Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countriesA J Bergman, I E van den Berg, W Brink, et al.
Human Genetics|January 1, 1996
Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationshipJ K Ploos van Amstel, A J Bergman, E A van Beurden, et al.
Clinical Pharmacology and Therapeutics|June 27, 2008
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsR Krishna, A J Bergman, B Jin, et al.
Pageof 2